Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study by Guillermo Garcia-Manero, Yasmin.

Slides:

Advertisements

Similar presentations

Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group by Phoenix.

Advertisements

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients by Mikkael A. Sekeres, Paul Elson,

Preliminary Results of a Multicenter Phase II Trial of 5-Day Decitabine as Front-Line Therapy for Elderly Patients with Acute Myeloid Leukemia (AML) Cashen.

Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)1 CC-486 (Oral.

FLT3 Internal Tandem Duplication(ITD) mutation in Acute Myeloid Leukemia and its clincopathological correlation – Study from a tertiary care centre in.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

A phase 2 study of the oral farnesyltransferase inhibitor tipifarnib in patients with refractory or relapsed acute myeloid leukemia by Jean-Luc Harousseau,

Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia by Thomas Lehrnbecher, Martin Zimmermann,

Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup by Marie-Anne Hospital, Thomas Prebet,

Gupta V, Tallman MS, Weisdorf DJ

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations by Mark J. Levis, Alexander E.

Multicolor Flow Cytometry and Multigene Next-Generation Sequencing Are Complementary and Highly Predictive for Relapse in Acute Myeloid Leukemia after.

Figure S1. AML550 and AML719 arrays

Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia

Anthracycline Dose Intensification in Acute Myeloid Leukemia

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with.

How Can we Improve Outcomes for the Elderly Patient with AML?

Long-term outcome of higher-risk MDS patients treated with azacitidine: an update of the GFM compassionate program cohort by Raphael Itzykson, Sylvain.

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but.

SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group by Yok-Lam Kwong, Won Seog Kim, Soon Thye.

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome–positive (Ph+) acute lymphoblastic.

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML by Nona Shayegi, Michael Kramer,

The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score by Ollivier Legrand, Jean-Yves Perrot, Marion Baudard, Annie.

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study by Daniel J. DeAngelo, Wendy.

Grövdal M et al. Blood 2008;112:Abstract 223.

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with.

NPM1 mutated AML can relapse with wild-type NPM1: persistent clonal hematopoiesis can drive relapse by Alexander Höllein, Manja Meggendorfer, Frank Dicker,

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p by James I. Barnes, Vasu Divi,

Cell-lineage level–targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes by Kazuaki Yokoyama, Eigo Shimizu, Nozomi.

New ELN Recommendations

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB (Alliance)‏ by Gail J. Roboz, Sumithra J. Mandrekar,

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation by Koichi Miyamura, Kazunori Ohnishi,

Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia.

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA by Nikola P. Konstandin, Friederike Pastore, Tobias Herold, Annika Dufour,

Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia George L. Chen, Hong Liu,

A Post Hoc Sensitivity Analysis of Survival Probabilities in a Multinational Phase III Trial of Decitabine in Older Patients With Newly Diagnosed Acute.

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories by Sanam Loghavi, Dawen Sui, Peng Wei, Guillermo Garcia-Manero, Sherry.

PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation by Wenbin Xiao, Maheetha.

by Hassan Awada, Yasunobu Nagata, Abhinav Goyal, Mohammad F

MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen by Haris Ali, Ibrahim Aldoss, Dongyun.

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Somatic HLA mutations expose the role of class I–mediated autoimmunity in aplastic anemia and its clonal complications by Daria V. Babushok, Jamie L. Duke,

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia by Lili Aslostovar, Allison L. Boyd, Mohammed.

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

by Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A

Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia by Anne Sophie Kubasch,

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes by Caroline J. McNamara, Tony Panzarella,

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy by Guillermo Montalban-Bravo,

Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.

Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia by Sebastian.

Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs by Preetesh Jain, Hagop Kantarjian,

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera by Nikolai A. Podoltsev, Mengxin.

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG.

The influence of stem cell source on transplant outcomes for pediatric patients with acute myeloid leukemia by Amy K. Keating, Jurgen Langenhorst, John.

CIP2A- and SETBP1-mediated PP2A inhibition reveals AKT S473 phosphorylation to be a new biomarker in AML by Claire M. Lucas, Laura J. Scott, Natasha Carmell,

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma by Maximilian Merz, Anna Jauch, Thomas Hielscher,

Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance by Alexandra M. Stevens, Jennifer.

Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML by Ronan T. Swords, Steven Coutre, Michael.

How I treat T-cell acute lymphoblastic leukemia in adults

Presentation transcript:

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study by Guillermo Garcia-Manero, Yasmin Abaza, Koichi Takahashi, Bruno C. Medeiros, Martha Arellano, Samer K. Khaled, Mrinal Patnaik, Olatoyosi Odenike, Hamid Sayar, Mohan Tummala, Prapti Patel, Lori Maness-Harris, Robert Stuart, Elie Traer, Kasra Karamlou, Abdulraheem Yacoub, Richard Ghalie, Ruben Giorgino, and Ehab Atallah BloodAdv Volume 3(4):508-518 February 26, 2019 © 2019 by The American Society of Hematology

Guillermo Garcia-Manero et al. Blood Adv 2019;3:508-518 © 2019 by The American Society of Hematology

Landscape of high-confidence somatic mutations detected in pretreatment BM samples. Landscape of high-confidence somatic mutations detected in pretreatment BM samples. (A) Number of mutations in each patient by cytogenetic risk group and type of AML. (B) Frequency of each type of mutation by patient. Each column represents 1 patient and each row represents 1 specific mutation. Guillermo Garcia-Manero et al. Blood Adv 2019;3:508-518 © 2019 by The American Society of Hematology

Outcomes of patients treated with pracinostat plus azacitidine. Outcomes of patients treated with pracinostat plus azacitidine. (A) OS for the whole cohort. (B) PFS for the whole population. (C) OS stratified by response. The plot shows how the effect of analyzing CR (as a baseline covariate) produces artificial difference; the difference between the overall curve and the curve obtained by censoring at time of CR gives a more realistic view. (D) OS stratified by cytogenetic risk group. Guillermo Garcia-Manero et al. Blood Adv 2019;3:508-518 © 2019 by The American Society of Hematology

Outcomes of patients treated with pracinostat plus azacitidine based on age, AML subtype, and ECOG status. Outcomes of patients treated with pracinostat plus azacitidine based on age, AML subtype, and ECOG status. (A) OS stratified by age. (B) OS stratified by AML subtype. (C) OS stratified by ECOG status. Guillermo Garcia-Manero et al. Blood Adv 2019;3:508-518 © 2019 by The American Society of Hematology

Representative cases of longitudinal sequencing analyses. Representative cases of longitudinal sequencing analyses. Each panel shows data for 1 patient. (A) Prolonged exposure to pracinostat plus azacitidine continued to lower mutants’ VAF. (B) Reexpansion of the original mutations on relapse after achieving CR. (C) Acquisition of a new mutation (RAD21) at the time of relapse with increase of original mutants' VAF at the time of cycle 6 before frank relapse. Guillermo Garcia-Manero et al. Blood Adv 2019;3:508-518 © 2019 by The American Society of Hematology